Clinical trial

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

NCT04763083

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-05-14

PhasePHASE1

Study timeline

Study start (actual)2021-05-14Date precision: day

Registry last updated2023-07-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Lymphocytic Leukaemiaunresolved

Small Lymphocytic Lymphomaunresolved

Mantle Cell Lymphomaunresolved

Follicular Lymphomaunresolved

Diffuse Large B Cell Lymphomaunresolved

Non-small Cell Lung Cancer (NSCLC)unresolved

Malignant Melanomaunresolved

Interventions

Sponsors & collaborators

NovalGen Ltd.lead sponsor

Mapped research locations

LondonUnited Kingdom2 ManchesterUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04763083 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.